Jazz Pharmaceuticals’ (JAZZ) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a report issued on Wednesday,Benzinga reports. They currently have a $210.00 price objective on the specialty pharmaceutical company’s stock.

JAZZ has been the subject of a number of other research reports. Cantor Fitzgerald downgraded Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and boosted their price target for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. Robert W. Baird boosted their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday, November 18th. Barclays reissued an “overweight” rating and issued a $200.00 target price (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Piper Sandler reissued an “overweight” rating and issued a $176.00 target price (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, February 26th. Finally, JPMorgan Chase & Co. increased their target price on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $189.40.

Jazz Pharmaceuticals Stock Up 1.7 %

JAZZ stock opened at $138.81 on Wednesday. The company has a market cap of $8.43 billion, a PE ratio of 19.55, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The business has a 50-day simple moving average of $128.14 and a 200 day simple moving average of $120.00. Jazz Pharmaceuticals has a 52 week low of $99.06 and a 52 week high of $148.06. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Insider Activity

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total transaction of $183,465.00. Following the completion of the sale, the chief executive officer now owns 439,744 shares of the company’s stock, valued at approximately $53,785,088.64. This represents a 0.34 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Neena M. Patil sold 3,800 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the sale, the executive vice president now directly owns 33,318 shares of the company’s stock, valued at $4,826,778.66. This represents a 10.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 25,193 shares of company stock valued at $3,533,122 over the last quarter. 4.20% of the stock is owned by company insiders.

Institutional Trading of Jazz Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. IFP Advisors Inc acquired a new stake in Jazz Pharmaceuticals during the 4th quarter valued at approximately $25,000. Quadrant Capital Group LLC increased its position in Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 101 shares during the period. Elequin Capital LP increased its position in Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 183 shares during the period. CoreFirst Bank & Trust acquired a new stake in Jazz Pharmaceuticals during the 4th quarter valued at approximately $28,000. Finally, Allianz SE acquired a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.